We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+14.44%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
+$407M
Cap. Flow
+$269M
Cap. Flow %
18.39%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
2
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$186M
2
VRNA
Verona Pharma
VRNA
+$186M
3
ALLO icon
Allogene Therapeutics
ALLO
+$19.7M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$59.7M
2
GERN icon
Geron
GERN
+$33.9M
3
KROS icon
Keros Therapeutics
KROS
+$26.7M
4
NRIX icon
Nurix Therapeutics
NRIX
+$3.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$1.2B 82.08%
15,397,975
+2,437,437
+19% +$186M
VRNA
2
DELISTED
Verona Pharma
VRNA
$246M 16.81%
3,923,204
+3,112,755
+384% +$186M
ALLO icon
3
Allogene Therapeutics
ALLO
$618M
$16.2M 1.11%
+10,449,791
New +$19.7M
GERN icon
4
Geron
GERN
$924M
– –
-9,569,835
Closed -$33.9M
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.5B
– –
-484,515
Closed -$59.7M
KROS icon
6
Keros Therapeutics
KROS
$211M
– –
-1,687,135
Closed -$26.7M
NRIX icon
7
Nurix Therapeutics
NRIX
$2.4B
– –
-163,681
Closed -$3.08M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q1 2025 Portfolio in Review

As of Q1 2025, Darwin Global Management held 7 positions worth $1.46B, up 39% from $1.06B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management deployed $269M of net new capital in Q1 2025, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Allogene Therapeutics: 10,449,791 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Jazz Pharmaceuticals, an estimated $59.7M sold.

  • Darwin Global Management's largest Q1 2025 buy was Allogene Therapeutics: 10,449,791 shares worth $16.2M.
  • Darwin Global Management added most to Insmed in Q1 2025, an estimated $186M increase.
  • Darwin Global Management fully exited Jazz Pharmaceuticals in Q1 2025, selling an estimated $59.7M.
  • Darwin Global Management's ten largest holdings make up 100% of its $1.46B portfolio in Q1 2025.
  • Darwin Global Management opened 1 new position and closed 4 in Q1 2025.
  • Darwin Global Management's portfolio value rose 39% quarter-over-quarter to $1.46B.

Based on Darwin Global Management's 13F filing for Q1 2025, filed 15 May 2025.